logo

This website uses cookies to ensure you get the best experience on our website.

Read through the Privacy Policy to understand better

 Go Back

National Kidney Foundation and Ardelyx, Inc. Survey Finds Dialysis Patients Struggle to Maintain Serum Phosphorus Levels

By AP News - Nov 04, 2022, 01:42 PM ET
Last Updated - Mar 19, 2024, 04:31 PM EDT
ARDX_Logo
Hyperphosphatemia is a serious condition resulting in an abnormally elevated level of phosphorus in the blood that is estimated to affect more than 745,000 dialysis patients in major developed countries

Ardelyx, Inc. (Nasdaq: ARDX) in partnership with the National Kidney Foundation (NKF), today announced results from a survey of patients with chronic kidney disease (CKD) on dialysis conducted to better understand patients' experience managing serum phosphorus levels

Majority of survey respondents call for new treatments to help manage phosphorus levels

WALTHAM, Mass. and NEW YORK, Nov. 4, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX) in partnership with the National Kidney Foundation (NKF), today announced results from a survey of patients with chronic kidney disease (CKD) on dialysis conducted to better understand patients' experience managing serum phosphorus levels. The survey found that more than 80% of respondents struggle to manage their serum phosphorus levels, with more than 90% citing a need for new treatment options.

Sponsored

"Despite best efforts with current treatment strategies, a significant proportion of patients have persistent hyperphosphatemia, placing them at an increased risk for mineral and bone disorder complications, including vascular disease," said Joseph Vassalotti, MD, chief medical officer for the National Kidney Foundation. "These survey results point to the difficulty people living with kidney diseases treated with dialysis have coping with low phosphorus diet and current medication schedules."

"We are proud to bring the patient voice to this important conversation," said Laura A. Williams, MD, chief medical officer of Ardelyx. "The idea for this survey, born from the Ardelyx Patient Advisory Council, provides great insight into the challenges patients face managing hyperphosphatemia and supports the need for innovation in this space. As a company committed to putting patients first, and as a CKD patient myself, we are proud of this collaborative effort that truly captures the voice of patients with kidney disease on dialysis."

By continuing to use this site, you agree to our terms and conditions
Sponsored
Sponsored
Sponsored
Our Offices
  • 10kInfo, Inc.
    13555 SE 36th St
    Bellevue, WA 98006
    Phone: +1 (425) 414-0184
  • 10kInfo Data Solutions, Pvt Ltd.
    Claywork Create
    11 km, Arakere Bannerghatta Rd, Omkar Nagar, Arekere,
    Bengaluru, Karnataka 560076
    Phone: +91 80 4902 2100
4.2 20250324